Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku, Actelion to Codevelop Macitentan for PAH
March 1, 2010
- Takashi Kodama to Be Reelected JPA President
March 1, 2010
- Medipal Ties Up with Medical Ikkou
March 1, 2010
- Dr Hakui Elected as President of Osaka Medical Association
March 1, 2010
- DSP Aims at Increasing Overseas Sales to 50% of Total Sales in FY2014
March 1, 2010
- FDA Approves Crestor for Preventive Purposes: AZ
March 1, 2010
- Korosho Asks Local Governments to Increase Stock of Relenza
March 1, 2010
- JMHA to Offer DB to Its Members to Compare Purchase Prices
February 22, 2010
- 4 Therapies Approved as Advanced Therapies
February 22, 2010
- METI to Foster Pharma Industry as Driver of Economic Growth
February 22, 2010
- Mergers May Take Place between Generic Companies: Mr Sawai
February 22, 2010
- Ethical Drugs Sales Up 4.2% in December: Crecon
February 22, 2010
- Daiichi Sankyo Applies for SUN Y7017 in Japan
February 22, 2010
- Prospects of Incretin-Related Drugs in Japan: 1
February 22, 2010
- Gemzar Approved for Breast Cancer in Japan: Ely Lilly
February 22, 2010
- Ranbaxy to Market Prasugrel in Mexico
February 22, 2010
- CDFS to Review Vectibix from Takeda
February 22, 2010
- Kyowa Kirin to Introduce Research Fellow System
February 22, 2010
- Taiyo to Increase Sales to Univ. Hospitals to Achieve ¥75 Bil. Sales by FY2013
February 22, 2010
- SRL to Acquire JCL
February 22, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…